奥洛兹美医疗 2025年季度报告

FORM10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember30, 2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 HALOZYME THERAPEUTICS, INC.(Exact name of registrant as specified in its charter) _______________________________________ (Registrant’s telephone number, including area code) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90 days.Yesx No¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes x No¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act.: Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐NoxThe number of outstanding shares (in thousands) of the registrant’s common stock, par value $0.001 per share, was117,597as of October27, 2025. HALOZYME THERAPEUTICS, INC.TABLE OF CONTENTS PARTI — FINANCIAL INFORMATION Item1.Financial StatementsCondensed Consolidated Balance Sheets (Unaudited) - September 30, 2025 and December 31, 20243Condensed Consolidated Statements of Income (Unaudited) - Three and Nine Months Ended September 30,2025 and 20244Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three and Nine Months EndedSeptember 30, 2025 and 20245Condensed Consolidated Statements of Cash Flows (Unaudited) - Nine Months Ended September 30, 2025 and20246Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - Three and Nine Months EndedSeptember 30, 2025 and 20247Notes to Condensed Consolidated Financial Statements (Unaudited)8Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations34Item3.Quantitative and Qualitative Disclosures About Market Risk54Item4.Controls and Procedures54 PARTII — OTHER INFORMATION Item1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securities and Use of ProceedsItem3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.Exhibits PART I — FINANCIAL INFORMATION HALOZYME THERAPEUTICS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)(In thousands, except per share amounts) HALOZYME THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF INCOME(Unaudited)(In thousands, except per share amounts) HALOZYME THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(Unaudited)(In thousands) HALOZYME THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands) HALOZYME THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1.Organization and Business Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences andoutcomes for emerging and established therapies. As the innovators of ENHANZEdrug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, ourcommercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids with the goal ofimproving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceuticalcompanies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds. We also develop,manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injectortechnologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability,and enhanced patient comfort and adherence.® Our ENHANZE